PF 114Alternative Names: PF-114; PF-114 mesylate
Latest Information Update: 08 Nov 2016
At a glance
- Originator Fusion Pharma
- Class Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic myeloid leukaemia
Most Recent Events
- 01 Jul 2016 Phase-I/II clinical trials in Chronic myeloid leukaemia in Russia (PO) (NCT02885766)